News Channels

16 Dec 2017 Cancer Research UK announces drug discovery collaboration with Celgene Corporation
16 Dec 2017 Celltrion Receives Positive CHMP Opinion for Herzuma® for Trastuzumab Biosimilar
16 Dec 2017 Takeda and TiGenix announce that Cx601 (darvadstrocel) has received a positive CHMP opinion to treat complex perianal fistulas in Crohn's disease
16 Dec 2017 Ultragenyx and Kyowa Kirin Announce Burosumab Receives Positive CHMP Opinion for the Treatment of X-Linked Hypophosphatemia in Children
16 Dec 2017 Ozempic® (semaglutide) recommended for approval by the European regulatory authorities
16 Dec 2017 FDA lifts clinical hold on fitusiran
15 Dec 2017 Orchard Therapeutics and Généthon Announce Gene Therapy Alliance in X-linked Chronic Granulomatous Disease
15 Dec 2017 Pfizer Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for the Treatment of Active Psoriatic Arthritis
15 Dec 2017 Galapagos exercises co-promotion option for filgotinib with collaboration partner Gilead Sciences in eight European countries
15 Dec 2017 Merck Provides Update on KEYNOTE-061, a Phase 3 Study of KEYTRUDA® (pembrolizumab) in Previously Treated Patients with Gastric or Gastroesophageal Junction Adenocarcinoma
14 Dec 2017 Pfizer Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Development for Moderate-to-Severe Atopic Dermatitis
14 Dec 2017 Jenrin Discovery’s IND Application for Its Peripherally Restricted Cannabinoid-1 Receptor Inverse Agonist NASH Compound Was Cleared by the FDA to Begin Phase 1 Clinical Trials
14 Dec 2017 reMYND Enters Into License Agreement to Further Develop Novel Treatments Improving Beta-cell Health and Insulin Signalling With Novo Nordisk
14 Dec 2017 Complix Receives €0.5 Million Grant to Further Develop its Pipeline of Proprietary Cell Penetrating Alphabodies™ Against Intracellular Cancer Targets
14 Dec 2017 Izana Bioscience Launches as New Clinical-Stage Translational Medicine Company Developing Namilumab in Ankylosing Spondylitis
14 Dec 2017 Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)
14 Dec 2017 OncoSec Announces Dosing of First Patient in Registration-Directed Phase 2b Clinical Trial, PISCES/KEYNOTE-695, of ImmunoPulse® IL-12 in Combination with Pembrolizumab
14 Dec 2017 Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)
14 Dec 2017 Amicus Therapeutics Submits New Drug Application to U.S. FDA for Migalastat for Treatment of Fabry Disease
14 Dec 2017 Cellectar Files IND for Phase 1 Trial of CLR 131 in Pediatric Cancers

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top